via GENZ – Daily Candlesticks.

Genzyme reject the offer at $60 per share. It is trading at $70. If I have to paid 17% more, I will just walk away. But if you look at the chart, I lot of smart money is bidding on Aventis will pay that 17% primeium.

Advertisements